Fleebs-Logo
Details werden geladen...

A single dose of psilocybin eased depression symptoms for months, our study found

Our trial found psilocybin worked fast and lasted months, but unpicking the drug’s true effect from patients’ expectations remains a challenge.

Ähnliche Seiten

https://www.sciencealert.com/a-single-dose-of-psilocybin-could-ease-depression-for-months-new-study-finds

A Single Dose of Psilocybin Could Ease Depression For Months, New Study Finds : ScienceAlert

https://www.sciencealert.com/a-single-dose-of-psilocybin-could-ease-depression-for-months-new-study-finds
https://www.finanznachrichten.de/nachrichten-2026-05/68598310-psilocybin-therapy-may-relieve-depression-for-months-study-finds-020.htm

Psilocybin Therapy May Relieve Depression For Months, Study Finds

https://www.finanznachrichten.de/nachrichten-2026-05/68598310-psilocybin-therapy-may-relieve-depression-for-months-study-finds-020.htm
https://thedebrief.org/psilocybin-helped-reduce-depression-symptoms-within-just-days-recent-clinical-trial-reveals/

Psilocybin Helped Reduce Depression Symptoms Within Just Days, Recent Clinical Trial Reveals - The Debrief

https://thedebrief.org/psilocybin-helped-reduce-depression-symptoms-within-just-days-recent-clinical-trial-reveals/
https://refractor.io/infectious-diseases/post-viral-depression-immune-system/

Signs of post-viral depression found in our immune system for the first time

https://refractor.io/infectious-diseases/post-viral-depression-immune-system/
https://www.manilatimes.net/2026/05/23/tmt-newswire/globenewswire/abivax-presents-first-quarter-2026-financial-results-and-reports-three-year-interim-data-from-study-108-a-phase-2a2b-open-label-extension-trial-of-obefazimod-following-dose-de-escalation-in-patients-with-ulcerative-colitis/2350350

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patient...

https://www.manilatimes.net/2026/05/23/tmt-newswire/globenewswire/abivax-presents-first-quarter-2026-financial-results-and-reports-three-year-interim-data-from-study-108-a-phase-2a2b-open-label-extension-trial-of-obefazimod-following-dose-de-escalation-in-patients-with-ulcerative-colitis/2350350
https://www.finanznachrichten.de/nachrichten-2026-05/68577444-eqs-news-abivax-abivax-presents-q1-2026-financial-results-and-reports-three-year-interim-data-from-study-108-a-phase-2a-2b-open-label-extension-tri-023.htm

EQS-News: ABIVAX: Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in P...

https://www.finanznachrichten.de/nachrichten-2026-05/68577444-eqs-news-abivax-abivax-presents-q1-2026-financial-results-and-reports-three-year-interim-data-from-study-108-a-phase-2a-2b-open-label-extension-tri-023.htm